Daratumumab/rituximab: Lack of efficacy.

This article discusses two case reports of patients who experienced lack of efficacy during treatment with rituximab and daratumumab for pure red cell aplasia (PRCA). The first patient, a 52-year-old man with high-risk acute myeloid leukemia, received a stem cell transplant and subsequently started receiving rituximab and daratumumab but remained transfusion dependent. After undergoing therapeutic plasma exchange, he became transfusion independent but developed transfusion-associated iron overload. The second patient, a 21-year-old man with severe aplastic anemia and paroxysmal nocturnal hemoglobinuria, also received rituximab and daratumumab but remained transfusion dependent. After therapeutic plasma exchange, he developed transfusion-associated iron overload and started chelation therapy. [Extracted from the article]